Antisense Oligonucleotide-Mediated Terminal Intron Retention of the SMN2 Transcript
The severe childhood disease spinal muscular atrophy (SMA) arises from the homozygous loss of the survival motor neuron 1 gene (SMN1). A homologous gene potentially encoding an identical protein, SMN2 can partially compensate for the loss of SMN1; however, the exclusion of a critical exon in the cod...
Main Authors: | Loren L. Flynn, Chalermchai Mitrpant, Ianthe L. Pitout, Sue Fletcher, Steve D. Wilton |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-06-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S216225311830012X |
Similar Items
-
A Precision Therapy Approach for Retinitis Pigmentosa 11 Using Splice-Switching Antisense Oligonucleotides to Restore the Open Reading Frame of PRPF31
by: Janya Grainok, et al.
Published: (2024-03-01) -
Antisense Oligonucleotide Mediated Splice Correction of a Deep Intronic Mutation in OPA1
by: Tobias Bonifert, et al.
Published: (2016-01-01) -
Targeted <i>SMN</i> Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies
by: Loren L. Flynn, et al.
Published: (2021-05-01) -
Efficient SMN Rescue following Subcutaneous Tricyclo-DNA Antisense Oligonucleotide Treatment
by: Valérie Robin, et al.
Published: (2017-06-01) -
Consequences of Making the Inactive Active Through Changes in Antisense Oligonucleotide Chemistries
by: Khine Zaw, et al.
Published: (2019-12-01)